Analysts' ratings for Neurocrine Biosciences NBIX over the last quarter vary from bullish to bearish, as provided by 16 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 9 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 0 | 0 | 0 |
| 3M Ago | 4 | 5 | 2 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $167.94, a high estimate of $216.00, and a low estimate of $138.00. This upward trend is apparent, with the current average reflecting a 5.89% increase from the previous average price target of $158.60.
Understanding Analyst Ratings: A Comprehensive Breakdown
A clear picture of Neurocrine Biosciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Anupam Rama | JP Morgan | Raises | Overweight | $173.00 | $169.00 |
| Jeffrey Hung | Morgan Stanley | Maintains | Overweight | $160.00 | $160.00 |
| Laura Chico | Wedbush | Maintains | Outperform | $152.00 | $152.00 |
| Ashwani Verma | UBS | Raises | Buy | $193.00 | $174.00 |
| Cory Kasimov | Evercore ISI Group | Announces | Outperform | $175.00 | - |
| David Hoang | Citigroup | Raises | Neutral | $150.00 | $140.00 |
| Sumant Kulkarni | Canaccord Genuity | Raises | Buy | $164.00 | $154.00 |
| Yatin Suneja | Guggenheim | Raises | Buy | $170.00 | $164.00 |
| Carter Gould | Barclays | Raises | Overweight | $169.00 | $150.00 |
| Evan Seigerman | BMO Capital | Raises | Market Perform | $138.00 | $129.00 |
| Jay Olson | Oppenheimer | Raises | Outperform | $216.00 | $200.00 |
| Andrew Fein | HC Wainwright & Co. | Raises | Buy | $160.00 | $150.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $150.00 | $150.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $170.00 | $140.00 |
| Jay Olson | Oppenheimer | Maintains | Outperform | $200.00 | $200.00 |
| Laura Chico | Wedbush | Maintains | Outperform | $147.00 | $147.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Neurocrine Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Neurocrine Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Neurocrine Biosciences analyst ratings.
All You Need to Know About Neurocrine Biosciences
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Understanding the Numbers: Neurocrine Biosciences's Finances
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Neurocrine Biosciences's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 22.57%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Neurocrine Biosciences's net margin is impressive, surpassing industry averages. With a net margin of 8.42%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE excels beyond industry benchmarks, reaching 1.88%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.29%, the company showcases effective utilization of assets.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.21, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
